A novel dual-payload ADC platform that can offer synergistic antitumoral efficacy of MMAE while reducing undesired side effects
European Journal of Cancer · 2026-11 · 248 · 117478
DOI: 10.1016/j.ejca.2026.117478 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von E. Choi und 15 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Choi, E., Kim, M., Lim, S., Lee, J., Jeon, H., Park, J., Lee, J., Hong, E., Jeong, D., Kim, S., Choi, J., Kim, Y., Kim, S., Kang, H., Kim, J., & Lee, C. (2026). A novel dual-payload ADC platform that can offer synergistic antitumoral efficacy of MMAE while reducing undesired side effects. European Journal of Cancer, 248, 117478. https://doi.org/10.1016/j.ejca.2026.117478
Vancouver
Choi E, Kim M, Lim S, Lee J, Jeon H, Park J, et al. A novel dual-payload ADC platform that can offer synergistic antitumoral efficacy of MMAE while reducing undesired side effects. European Journal of Cancer. 2026;248:117478. doi:10.1016/j.ejca.2026.117478
BibTeX
@article{Choi2026,
author = {Choi, E. and Kim, M. and Lim, S. and Lee, J. and Jeon, H. and Park, J. and Lee, J. and Hong, E. and Jeong, D. and Kim, S. and Choi, J. and Kim, Y. and Kim, S. and Kang, H. and Kim, J. and Lee, C.S.},
title = {A novel dual-payload ADC platform that can offer synergistic antitumoral efficacy of MMAE while reducing undesired side effects},
journal = {European Journal of Cancer},
year = {2026},
volume = {248},
pages = {117478},
doi = {10.1016/j.ejca.2026.117478}
}
EUVIMED